Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baclofen/naltrexone/sorbitol - Pharnext

Next Previous
Drug Profile

Baclofen/naltrexone/sorbitol - Pharnext

Alternative Names: (RS)-baclofen/D-sorbitol/naltrexone; (RS)-baclofen/naltrexone/D-sorbitol; Baclofen/sorbitol/naltrexone; Naltrexone/baclofen/sorbitol; Naltrexone/sorbitol/baclofen; PXT-03003; PXT-3003; Sorbitol/baclofen/naltrexone; Sorbitol/naltrexone/baclofen; SYNGILITY

Latest Information Update: 18 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharnext
  • Developer GeneNet; Pharnext
  • Class Alcohols; Aminobutyric acids; Analgesics; Anti-inflammatories; Antineoplastics; Antispastics; Antivirals; Cyclic ethers; Cyclohexanes; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Furans; Irritable bowel syndrome therapies; Ketones; Morphinans; Muscle relaxants; Naphthols; Non-opioid analgesics; Phenanthrenes; Phenols; Piperidines; Small molecules; Sugar alcohols
  • Mechanism of Action GABA B receptor agonists; Opioid receptor antagonists; PMP22 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Charcot-Marie-Tooth disease
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Charcot-Marie-Tooth disease

Most Recent Events

  • 07 Aug 2026 Neovacs and an undisclosed American biopharmaceutical company entered into an agreement for PXT 3003
  • 14 Jan 2026 Preregistration for Charcot-Marie-Tooth disease (In adolescents, In adults) in China (PO)
  • 19 Dec 2024 No development reported - Phase-III for Charcot-Marie-Tooth disease (In adolescents, In adults) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top